• From P2RX1 Mechanism to Apoptosis Readouts

  2026-08-22

  Mechanistic studies in Philadelphia chromosome-positive acute lymphoblastic leukemia show how P2RX1-linked calcium dysregulation can converge on mitochondrial apoptosis. This thought-leadership guide translates that biology into a rigorous Annexin V-Cy5/DAPI workflow for distinguishing phosphatidylserine exposure, membrane compromise, and treatment response.

• BODIPY 581/591 C11 for Lipid Oxidative Stress

  2026-08-21

  BODIPY 581/591 C11 converts membrane oxidation into a quantitative red-to-green fluorescence ratio, making it useful for live-cell lipid peroxidation detection and antioxidant capacity evaluation. This workflow shows how to apply the probe to acute myocardial infarction and nanozyme studies while avoiding overinterpretation of signals from ROS that the dye does not directly report.

• Isradipine (Dynacirc) for Calcium Signaling Workflows

  2026-08-20

  Isradipine (Dynacirc) provides a practical way to interrogate L-type calcium influx across vascular and neuronal models. This guide connects stock preparation, electrophysiology, calcium imaging, and troubleshooting to better-designed hypertension research and excitotoxicity assays.

• Azilsartan (TAK-536) in RAS Research

  2026-08-20

  Azilsartan (TAK-536) provides selective AT1 receptor blockade for separating renin–angiotensin signaling from broader inflammatory effects. This guide translates the astrocyte–microglia findings of a recent reference study into practical dosing, assay design, controls, and troubleshooting steps.

• Dual-Action Control of p38α Dephosphorylation

  2026-08-19

  The reference preprint shows that selected kinase inhibitors can do more than suppress p38α catalytic activity: they can also expose its activation-loop phospho-threonine to the WIP1 phosphatase. This conformational mechanism offers a framework for designing inhibitors that shorten kinase signaling duration as well as block kinase function.

• Azilsartan Medoxomil: AT1 Blockade in Hypertension

  2026-08-19

  This 2017 MiniReview synthesizes the pharmacology, pharmacokinetics, clinical evidence, and tolerability of azilsartan medoxomil, emphasizing its unusually persistent interaction with the angiotensin II type 1 receptor. Its key implication is that prolonged AT1 receptor antagonism may contribute to strong blood-pressure reduction, although evidence for reduced mortality remained unresolved.

• Telmisartan in Cardiac Hypertrophy Research

  2026-08-18

  Telmisartan is an angiotensin II receptor antagonist used to model AT1-receptor blockade in hypertension research and cardiovascular disease research. Its defined chemical profile and DMSO solubility support controlled in vitro workflows, while recent cardiac-hypertrophy work clarifies why AT1R controls should be interpreted separately from RIP3/CaMKII mechanisms.

• STNvac Drives TLS Formation in HCC

  2026-08-18

  Lin et al. developed a spleen-targeted neoantigen mRNA vaccine that produced strong antitumor activity in orthotopic hepatocellular carcinoma models. The study links vaccine efficacy to ISG15-positive CD8-positive T cells, GZMA-F2R signaling, and tertiary lymphoid structure formation, offering a mechanistic framework for improving cancer mRNA vaccine design.

• L-Phenylephrine and Sex-Aware α1A Signaling

  2026-08-17

  L-Phenylephrine offers a focused way to interrogate adrenergic α1A receptor biology across vascular, cardiac, and neural models. By combining its receptor profile with sex-aware hypertension research, translational teams can design experiments that separate receptor mechanism from autonomic, hormonal, and systemic context.

• Fosinopril Clinical Pharmacokinetics and Potential

  2026-08-17

  The 1997 review of fosinopril integrates molecular ACE inhibition with absorption, active-metabolite disposition, pharmacodynamics, organ dysfunction, and drug interactions. Its central translational insight is that biliary as well as renal elimination of fosinoprilat may distinguish this prodrug from predominantly renally cleared ACE inhibitors, with implications for hypertension research and cardiovascular pharmacology.

• Angiotensin II: Reliable Vascular Assays

  2026-08-16

  This scenario-driven guide explains how Angiotensin II (SKU A1042) can support controlled cell viability, proliferation, cytotoxicity, and vascular remodeling experiments. It combines practical peptide handling, concentration selection, assay interpretation, and evidence from an abdominal aortic aneurysm study to improve experimental clarity.

• Losartan: From AT1 Blockade to Matrix Mechanics

  2026-08-15

  Losartan is an angiotensin II receptor antagonist with applications extending from hypertension research to mechanobiology. This article explains how to design assays that separate AT1 signaling, vascular smooth muscle cell proliferation inhibition, and tumor-matrix remodeling effects.

• Fangchinoline Restores Lysosomal Defense Against H1N1

  2026-08-15

  Cheng and colleagues identify fangchinoline as a lysosome-directed antiviral compound that restores TFEB-dependent lysosomal gene expression and interferes with H1N1 entry. The study combines Connectivity Map screening, transcriptomic profiling, imaging, autophagy analysis, time-resolved infection assays, and in vivo validation to define a host-directed mechanism with potential relevance to influenza research.

• WNT5a/GSK3/β-Catenin Control of FAP Adipogenesis

  2026-08-14

  The reference study identifies the WNT5a/GSK3/β-catenin axis as a regulatory circuit that restrains adipogenic differentiation of skeletal muscle fibro/adipogenic progenitors (FAPs). By integrating pharmacological screening, mass cytometry, transcriptomic datasets, network modeling, and mouse injury models, it links pathway disruption to fatty degeneration and altered muscle regeneration.

• BIRB 796 (Doramapimod): From Binding to Biology

  2026-08-13

  BIRB 796, also known as Doramapimod, illustrates how allosteric p38α MAPK inhibition can connect kinase selectivity, signaling kinetics, cytokine production inhibition, and translational assay design. This thought-leadership analysis integrates product evidence with recent structural insights into kinase dephosphorylation to help researchers build more informative inflammation and apoptosis workflows.

450 records 7/30 page Previous Next First page 上5页 678910 下5页 Last page